The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
September 16, 2016 – Vice President Joe Biden announced a series of new steps focused on increasing access to information about clinical trials and improving the efficiency of our clinical research system. These steps include (1) making it easier for participants to find clinical trial opportunities as quickly as possible, (2) incentivizing new ways of designing clinical trials to maximize participation while minimizing burden and risk, and (3) strengthening the transparency of clinical trials and trial results.
He stated, “Clinical trials are essential for developing new and more effective cancer diagnostics and treatments. But right now, less than five percent of cancer patients enroll in a clinical trial, often because patients and doctors don’t know what trials are available. We can do better—and we are.”
These steps include:
- The National Cancer Institute (NCI) of the National Institutes of Health (NIH) Launches Redesign of Cancer Clinical Trial Information Available through Trials.Cancer.gov
- The Food and Drug Administration (FDA) will Encourage Use of Innovative Clinical Trial Designs
- The Department of Health and Human Services (HHS) Enhances Clinical Trial Registration and Results Reporting through Final Rule
Access the new Patient Friendly Clinical Trial Search Engine here https://www.cancer.gov/about-cancer/treatment/clinical-trials/search or http://trials.cancer.gov
Read more here:
http://time.com/4494104/joe-biden-cancer-moonshot/?xid=emailshare
Related posts
